Inbio ventures

Our Portfolio Company, Jounce Therapeutics, Announced Pricing of Initial Public Offering

Moscow, Russia, Jan. 27, 2017 – A portfolio company of Pharmstandard International, S.A., Jounce Therapeutics, Inc., a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced the pricing of its initial public offering of 6,365,000 shares of common stock at a public offering price of $16.00 per share for aggregate gross proceeds of $101,840,000. In addition, Jounce granted the underwriters a 30-day option to purchase up to 954,750 additional shares of its common stock at the initial public offering price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on January 27, 2017 under the ticker symbol “JNCE.”

J.P. Morgan and Cowen and Company are acting as joint book-running managers for the offering. Wells Fargo Securities is acting as lead manager and Baird is acting as a co-manager for the offering.

A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on January 26, 2017. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, telephone: (631) 274-2806.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of our Translational Science Platform, we first focus on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient. Jounce was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. In July 2016, Jounce announced a global strategic collaboration with Celgene Corporation.

Media Contact:

Dan Budwick

Pure Communications, Inc.

(973) 271-6085

dan@purecommunicationsinc.com

Investor Contact:

Beth DelGiacco

Stern Investor Relations, Inc.

(212) 362-1200

beth@sternir.com

 

About Pharmstandard International S.A. / Inbio Ventures

Pharmstandard International S.A. – is a company with the main focus on venture investments in innovative medicines/therapies with strong potential both globally and in Russia. Pharmstandard International S.A. is a fully owned subsidiary of PJSC Pharmstandard (LSE:PHST) – Russia’s leading pharmaceutical producer. For more information, please visit: www.pharmstd.lu

Inbio Ventures JSC – is a management company representing Pharmstandard International S.A., and providing professional support in venture transactions. For more information, please visit: http://www.inbio-ventures.com/

Pharmstandard International Represented by Inbio Ventures Participated in Series B Financing of Neon Therapeutics

Moscow, Russia – January 5, 2017 – Pharmstandard International and Inbio ventures today have announced successful completion of Series B financing in Neon therapeutics, thus adding the 10th equity investment to the portfolio. Neon is immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer. The proceeds will be used to advance the lead program, NEO-PV-01, a fully personalized neoantigen vaccine, through an ongoing Phase 1b clinical trial. In addition, this investment will support preclinical development of NEO-PTC-01, a personalized adoptive T cell program, and the Shared Neoantigen Program.
The $70 million Series B financing was led by Partner Fund Management and joined by existing investors Third Rock Ventures and Access Industries. Besides Pharmstandard International additional new investors included Fidelity Management & Research Company, Wellington Management Company and Nextech Invest.
“We are pleased to join a strong syndicate of investors,” commented Alexey Vinogradov, chief executive officer of Inbio Ventures, a management company representing Pharmstandard International S.A. “With outstanding quality of innovation and the team, Neon is poised to lead the field of neoantigen-based therapeutics, one of the most promising topics in cancer immunotherapy today.”
“The investor quality in this financing reflects the promise of the neoantigen biology platform, as well as our leading position,” said Hugh O’Dowd, chief executive officer of Neon Therapeutics.

About Neon Therapeutics
Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer. A neoantigen-based product engine allows Neon to develop multiple treatment modalities, including next-generation vaccines and T cell therapies targeting both personalized and shared neoantigens. Neon’s lead program is a personalized neoantigen vaccine that builds upon years of research and development at the Broad Institute and Dana-Farber Cancer Institute, and is already in clinical trials. For more information, please visit www.neontherapeutics.com.

About Pharmstandard International S.A. / Inbio Ventures
Pharmstandard International S.A. – is a company with the main focus on venture investments in innovative medicines/therapies with strong potential both globally and in Russia. Pharmstandard International S.A. is a fully owned subsidiary of PJSC Pharmstandard (LSE:PHST) – Russia’s leading pharmaceutical producer. For more information, please visit: www.pharmstd.lu.
Inbio Ventures JSC – is a management company representing Pharmstandard International S.A., and providing professional support in venture transactions. For more information, please visit: http://www.inbio-ventures.com/

Pharmstandard International S.A. Represented by Inbio Ventures Leads a $20M Syndicated Series C Financing in Avelas Biosciences

Moscow, August 18, 2016 – Pharmstandard International, S.A., led the the Series C financing which raised $20 million in new funds for Avelas Biosciences. Along with Pharmstandard International, S.A., the syndicate included other new investors Ervington Investments Limited, and Alexandria Equities, LLC, as well as existing investors Avalon Ventures, Bregua Corporation, and WuXi Healthcare Ventures.

Avelas Biosciences, Inc., is a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment. The proceeds from Series C financing will be used to advance AVB-620, a “cancer illuminator,” into late-stage clinical trials, and to develop new targeted therapeutics for cancer, as well as for general corporate purposes.

In conjunction with the financing, Andrei Petrov, Ph.D, the chief executive officer and managing partner at Inbio Ventures, has joined Avelas Bioscience’s board of directors. At the same time, Kevin Kinsella and Nikolay Savchuk will be stepping down as directors of the company.

“I am delighted to have some of the world’s most prominent healthcare investors participate in our Series C financing, led by Pharmstandard,” said Carmine N. Stengone, president and chief executive officer of Avelas Biosciences. “Strengthened by this fundraising, I believe Avelas is well-positioned to further the development of AVB-620 and advance new therapeutic candidates – two exciting product opportunities that could make meaningful contributions to cancer diagnosis and treatment.”

Avelas’ core technology takes advantage of cancer’s inherent biochemical pathology to deliver cargo, either therapeutic or imaging, to the cancer site. The first product candidate, AVB-620, is a fluorescent, cancer-illuminating probe that “lights up” when it interacts with cancer cells. The purpose of AVB-620 is to enable cancer surgeons to distinguish between tumor and healthy tissue during surgery. AVB-620 may be able to offer the necessary real-time information needed by surgeons to visualize and excise cancerous tissue while they operate, avoiding the need for additional surgeries.

About Avelas Biosciences

Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. The company’s lead product candidate, AVB-620, is in a Phase 1b trial in breast cancer to assess safety, pharmacokinetics, and fluorescence properties using tissue image analysis. Avelas was founded by Avalon Ventures on technology from Nobel laureate Roger Y. Tsien, Ph.D. For additional information, please visit www.avelasbio.com.

Our Portfolio Company, Protagonist Therapeutics, has successfully completed Initial Public Offering

Protagonist is the fourth company in our portfolio that successfully went public on NASDAQ. Pharmstandard International has participated in the offering. The upsized IPO was completed at $12 per share that represents a solid step-up to previous investment rounds

Moscow, Russia, August 11, 2016 – A portfolio company of Pharmstandard International, S.A., Protagonist Therapeutics, Inc. (NASDAQ: PTGX), that is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs, announced on August 10, 2016 the pricing of its initial public offering of 7,500,000 shares of common stock, at a price to the public of $12 per share, before underwriting discounts and commissions. The shares began trading on The NASDAQ Global Market on August 11, 2016, under the symbol “PTGX.” In addition, Protagonist has granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares at the initial public offering price, less underwriting discounts and commissions.
This offering closed on August 16, 2016, subject to customary closing conditions. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on August 10, 2016.

About Pharmstandard International S.A. / Inbio Ventures

Pharmstandard International S.A. – is a company with the main focus on venture investments in innovative medicines/therapies with strong potential both globally and in Russia. Pharmstandard International S.A. is a fully owned subsidiary of PJSC Pharmstandard (LSE:PHST) – Russia’s leading pharmaceutical producer. For more information, please visit: www.pharmstd.lu
Inbio Ventures JSC – is a management company representing Pharmstandard International S.A., and providing professional support in venture transactions. For more information, please visit: http://www.inbio-ventures.com/